跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Pidilizumab

首页药物Pidilizumab

Investigational

Biotech

Pidilizumab

未知生产厂商

Pidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).

生成 AI 研报

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Pidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).

技术标识符

CAS 编号: 1036730-42-3
UNII ID: B932PAQ1BQ

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

Method for treating an individual suffering from a chronic infectious disease and cancer
US 11213552 B2申请人: KOVARIK JOSEPH E优先权: 2021
US
2 件公开
Pidilizumab monoclonal antibody therapy following stem cell transplantation
US 9580504 B1申请人: CURETECH LTD优先权: 2014
US
ENHANCING T-CELL FUNCTION AND TREATING T-CELL DYSFUNCTIONAL DISORDER WITH COMBINATION OF LSD INHIBITOR AND PD1 BINDING ANTAGONIST
CN 111655247 A申请人: UNIV CANBERRA优先权: 2017
CN
Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
US 12053523 B2申请人: UNIV NORTH CAROLINA STATE优先权: 2018
US
Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US 11026982 B2申请人: KOVARIK JOSEPH E优先权: 2020
US
Method for treating an individual suffering from bladder cancer
US 11642382 B2申请人: SEED HEALTH INC优先权: 2022
US
Method for treating individuals having cancer and who are receiving cancer immunotherapy
US 11672835 B2申请人: SEED HEALTH INC优先权: 2022
US